ARMP Quote, Financials, Valuation and Earnings

AIM ImmunoTech has a net margin of -2301.55% compared to Armata Pharmaceuticals, Inc.'s net margin of -10571.43%. Armata Pharmaceuticals, Inc.'s return on equity of -- beat AIM ImmunoTech's return on equity of -256.33%.

Armata Pharmaceuticals, Inc. has a consensus price target of $9.00, signalling upside risk potential of 27.66%. On the other hand AIM ImmunoTech has an analysts' consensus of $4.50 which suggests that it could grow by 11066.25%. Given that AIM ImmunoTech has higher upside potential than Armata Pharmaceuticals, Inc., analysts believe AIM ImmunoTech is more attractive than Armata Pharmaceuticals, Inc..

Armata Pharmaceuticals, Inc. has a beta of 1.292, which suggesting that the stock is 29.177% more volatile than S&P 500. In comparison AIM ImmunoTech has a beta of 0.760, suggesting its less volatile than the S&P 500 by 23.953%.

Armata Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AIM ImmunoTech offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Armata Pharmaceuticals, Inc. pays -- of its earnings as a dividend. AIM ImmunoTech pays out -- of its earnings as a dividend.

Armata Pharmaceuticals, Inc. quarterly revenues are $1.2M, which are larger than AIM ImmunoTech quarterly revenues of $35K. Armata Pharmaceuticals, Inc.'s net income of -$26.7M is lower than AIM ImmunoTech's net income of -$3.7M. Notably, Armata Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while AIM ImmunoTech's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Armata Pharmaceuticals, Inc. is 58.48x versus 13.27x for AIM ImmunoTech. Usually stocks with elevated PS ratios are considered overvalued.

Integer Holdings Corp. has a net margin of -2301.55% compared to Armata Pharmaceuticals, Inc.'s net margin of 8.5%. Armata Pharmaceuticals, Inc.'s return on equity of -- beat Integer Holdings Corp.'s return on equity of 5.26%.

Armata Pharmaceuticals, Inc. has a consensus price target of $9.00, signalling upside risk potential of 27.66%. On the other hand Integer Holdings Corp. has an analysts' consensus of $85.57 which suggests that it could grow by 1.5%. Given that Armata Pharmaceuticals, Inc. has higher upside potential than Integer Holdings Corp., analysts believe Armata Pharmaceuticals, Inc. is more attractive than Integer Holdings Corp..

Armata Pharmaceuticals, Inc. has a beta of 1.292, which suggesting that the stock is 29.177% more volatile than S&P 500. In comparison Integer Holdings Corp. has a beta of 0.785, suggesting its less volatile than the S&P 500 by 21.493%.

Armata Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Integer Holdings Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Armata Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Integer Holdings Corp. pays out -- of its earnings as a dividend.

Armata Pharmaceuticals, Inc. quarterly revenues are $1.2M, which are smaller than Integer Holdings Corp. quarterly revenues of $466.6M. Armata Pharmaceuticals, Inc.'s net income of -$26.7M is lower than Integer Holdings Corp.'s net income of $39.7M. Notably, Armata Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Integer Holdings Corp.'s PE ratio is 35.30x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Armata Pharmaceuticals, Inc. is 58.48x versus 1.63x for Integer Holdings Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Liquidia Corp. has a net margin of -2301.55% compared to Armata Pharmaceuticals, Inc.'s net margin of -6.5%. Armata Pharmaceuticals, Inc.'s return on equity of -- beat Liquidia Corp.'s return on equity of -221.75%.

Armata Pharmaceuticals, Inc. has a consensus price target of $9.00, signalling upside risk potential of 27.66%. On the other hand Liquidia Corp. has an analysts' consensus of $44.00 which suggests that it could grow by 22.7%. Given that Armata Pharmaceuticals, Inc. has higher upside potential than Liquidia Corp., analysts believe Armata Pharmaceuticals, Inc. is more attractive than Liquidia Corp..

Armata Pharmaceuticals, Inc. has a beta of 1.292, which suggesting that the stock is 29.177% more volatile than S&P 500. In comparison Liquidia Corp. has a beta of 0.484, suggesting its less volatile than the S&P 500 by 51.629%.

Armata Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Liquidia Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Armata Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Liquidia Corp. pays out -- of its earnings as a dividend.

Armata Pharmaceuticals, Inc. quarterly revenues are $1.2M, which are smaller than Liquidia Corp. quarterly revenues of $54.3M. Armata Pharmaceuticals, Inc.'s net income of -$26.7M is lower than Liquidia Corp.'s net income of -$3.5M. Notably, Armata Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Liquidia Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Armata Pharmaceuticals, Inc. is 58.48x versus 44.27x for Liquidia Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Protalix Biotherapeutics, Inc. has a net margin of -2301.55% compared to Armata Pharmaceuticals, Inc.'s net margin of 13.19%. Armata Pharmaceuticals, Inc.'s return on equity of -- beat Protalix Biotherapeutics, Inc.'s return on equity of 12.06%.

Armata Pharmaceuticals, Inc. has a consensus price target of $9.00, signalling upside risk potential of 27.66%. On the other hand Protalix Biotherapeutics, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 450%. Given that Protalix Biotherapeutics, Inc. has higher upside potential than Armata Pharmaceuticals, Inc., analysts believe Protalix Biotherapeutics, Inc. is more attractive than Armata Pharmaceuticals, Inc..

Armata Pharmaceuticals, Inc. has a beta of 1.292, which suggesting that the stock is 29.177% more volatile than S&P 500. In comparison Protalix Biotherapeutics, Inc. has a beta of -0.251, suggesting its less volatile than the S&P 500 by 125.1%.

Armata Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Armata Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Protalix Biotherapeutics, Inc. pays out -- of its earnings as a dividend.

Armata Pharmaceuticals, Inc. quarterly revenues are $1.2M, which are smaller than Protalix Biotherapeutics, Inc. quarterly revenues of $17.9M. Armata Pharmaceuticals, Inc.'s net income of -$26.7M is lower than Protalix Biotherapeutics, Inc.'s net income of $2.4M. Notably, Armata Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Protalix Biotherapeutics, Inc.'s PE ratio is 28.78x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Armata Pharmaceuticals, Inc. is 58.48x versus 2.54x for Protalix Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.